10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo; Abhishek Maiti; Caitlin R. Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval Daver; Tapan M. Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C. Issa; Guillermo Montalban‐Bravo; Nicholas J. Short; Musa Yılmaz; Prithviraj Bose; Elias Jabbour; Koichi Takahashi; Jan A. Burger; Guillermo Garcia‐Manero; Nitin Jain; Steven M. Kornblau; Philip A. Thompson; Zeev Estrov; Lucia Masárová; Koji Sasaki; Srđan Verstovšek; Alessandra Ferrajoli; William Weirda; Sa A. Wang; Sergej Konoplev; Zhining Chen; Sherry Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S. Welch; Hagop M. Kantarjian; Marina Konopleva

doi:10.1016/s2352-3026(20)30210-6

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Caitlin R. Rausch(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Kiran Naqvi(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Nitin Jain(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), William Weirda(The University of Texas MD Anderson Cancer Center), Sa A. Wang(The University of Texas MD Anderson Cancer Center), Sergej Konoplev(The University of Texas MD Anderson Cancer Center), Zhining Chen(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Jing Ning(The University of Texas MD Anderson Cancer Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), John S. Welch(Washington University in St. Louis), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center)

The Lancet Haematology

September 5, 2020

10.1016/s2352-3026(20)30210-6

Cited by 328Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis